Tag Archives: R&D

Verastem director Brian Stuglik sells shares worth $937,000, sparking curiosity among investors and industry watchers. The move comes amidst a backdrop of recent developments at Verastem, a company focused on developing innovative cancer therapies. Stuglik, a seasoned executive with a deep understanding of the pharmaceutical landscape, has been a key …

Read More »